Participant‐reported improvement of hirsutism 4‐point Likert scale · women with hirsutism
Flutamide 250 mg b.i.d. may leads to higher participant‐reported improvement of hirsutism 4‐point Likert scale compared with placebo (low certainty).
1 finding from 1 review
Change in health‐related quality of life (HRQOL) ‐ not measured · women with hirsutism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Primary outcome: Histological complete response ( available‐case analysis) No residual LM in staged excision 2 months post‐treatment · participants with melanoma in situ, including lentigo maligna
Imiquimod 5% cream with tazarotene 0.1% gel showed no clear difference in primary outcome: Histological complete response (intention‐to‐treat)… compared with imiquimod 5% cream alone (low certainty).
2 findings from 1 review
Discontinuation of treatment due to side effects ( · participants with melanoma in situ, including lentigo maligna
Imiquimod 5% cream with tazarotene 0.1% gel showed no clear difference in secondary outcome: Discontinuation of treatment because of harms… compared with imiquimod 5% cream alone (low certainty).
1 finding from 1 review
Secondary outcome: Inflammatory response (number of lesions with grade 2 or 3) Grade 2 or 3 Inflammation² · participants with melanoma in situ, including lentigo maligna
Imiquimod 5% cream with tazarotene 0.1% gel may leads to higher secondary outcome: Inflammatory response (number of lesions with… compared with imiquimod 5% cream alone (low certainty).
1 finding from 1 review
Secondary outcome: Inflammatory response (overall Inflammation score) for all participants Mean grade of inflammation in each group² · participants with melanoma in situ, including lentigo maligna
1 finding from 1 review
Pain reduction (VAS 0-10) · People with erosive oral lichen planus
Topical tacrolimus 0.1% ointment showed no clear difference in pain reduction (VAS 0-10) compared with topical clobetasol propionate 0.05% ointment; GRADE not reported.
1 finding from 1 review
Physician Global Assessment (Thongprasom score) · People with erosive oral lichen planus
0.1% triamcinolone acetonide in orabase showed no clear difference in physician Global Assessment (Thongprasom score) compared with ciclosporin solution; GRADE not reported.
1 finding from 1 review
Partial response (remarkably effective or effective) · People with erosive oral lichen planus
Radix tripterygium hypoglaucum tablet (THT) led to lower partial response (remarkably effective or effective) compared with tripterygium glucosides tablet (TGT); GRADE not reported.
2 findings from 1 review
Physician Global Assessment (Thongprasom score) · People with erosive oral lichen planus
Topical clobetasol propionate 0.025% showed no clear difference in physician Global Assessment (Thongprasom score) compared with topical clobetasol propionate 0.05%; GRADE not reported.
1 finding from 1 review
Secondary outcome: Dermatology Quality of Life measure · People with erosive oral lichen planus
1 finding from 1 review
Physician Global Assessment (Thongprasom score) · People with erosive oral lichen planus
Topical ciclosporin 1.5% gel showed no clear difference in physician Global Assessment (Thongprasom score) compared with topical clobetasol propionate 0.025% gel; GRADE not reported.
1 finding from 1 review
Physician Global Assessment (surface of erosive lesions) · People with erosive oral lichen planus
1% pimecrolimus cream showed no clear difference in physician Global Assessment (surface of erosive lesions) compared with placebo (vehicle cream); GRADE not reported.
1 finding from 1 review
Pain reduction (VAS 0-100) · People with erosive oral lichen planus
0.1% triamcinolone acetonide in orabase led to higher pain reduction (VAS 0-100) compared with ciclosporin solution; GRADE not reported.
1 finding from 1 review
Relapse rate when medications stopped · People with erosive oral lichen planus
1 finding from 1 review
Topical clobetasol gave less stable results than ciclosporin when therapy ended and showed a higher incidence of side-effects (Conrotto 2006, n=40).
1 study · 40 participants
GRADE not reported
Pain reduction (VAS) · People with erosive oral lichen planus
Topical clobetasol propionate 0.025% showed no clear difference in pain reduction (VAS) compared with topical clobetasol propionate 0.05%; GRADE not reported.
1 finding from 1 review
Side effects · People with erosive oral lichen planus
1 finding from 1 review
Table 3 (Side-effects). Passeron 2007: 1% pimecrolimus well-tolerated, transient burning (2) during the first 2 weeks. Swift 2005: pimecrolimus - slight burning of the tip of the tongue after applying 1% pimecrolimus…
3 studies · 52 participants
GRADE not reported
Physician Global Assessment (strong improvement) · People with erosive oral lichen planus
1% pimecrolimus cream led to higher physician Global Assessment (strong improvement) compared with placebo (vehicle cream); GRADE not reported.
1 finding from 1 review
Participant global self-assessment · People with erosive oral lichen planus
1 finding from 1 review
One study (Passeron 2007) assessed participant global self-assessment on a 5-point scale: 5/6 participants in the 1% pimecrolimus group rated their improvement as moderate or important versus 1/6 in the placebo group…
1 study · 12 participants
GRADE not reported
Pain reduction (VAS 0-100) · People with erosive oral lichen planus
1 finding from 1 review
In the Hegarty 2002 cross-over trial (n=22), no statistical testing of the pain score (VAS 0 to 100) was reported; it is not clear whether the difference is statistically significant (fluticasone mean score 19.8 versus…
1 study · 22 participants
GRADE not reported